Director Declaration (6086W)
February 01 2012 - 8:26AM
UK Regulatory
TIDMHIK
RNS Number : 6086W
Hikma Pharmaceuticals Plc
01 February 2012
Michael Ashton Appointment to PuriCore plc
London, 1 February 2012 - Hikma Pharmaceuticals PLC (LSE: HIK)
(DIFX: HIK) makes this announcement in accordance with Listing Rule
LR 9.6.14, which requires Hikma to notify the market when directors
of Hikma become directors of other publicly traded companies.
Mr. Michael Ashton, an independent non-executive director of
Hikma, has been appointed as an independent non-executive director
of PuriCore plc (LSE: PURI) with effect from 1 February 2012.
"PuriCore plc (LSE: PURI) is a water-based clean technology
company focused on developing and commercialising proprietary green
solutions that safely, effectively, and naturally kill infectious
pathogens without causing harm to human health or the environment.
PuriCore's patented, proprietary technology offers a safe and
non-hazardous approach to disinfection and sanitisation." Source:
PuriCore plc
- ENDS -
Enquiries:
Hikma Pharmaceuticals PLC
Henry Knowles, Company Secretary +44 (0)20 7399 2760
Notes to Editors
About Hikma
Hikma Pharmaceuticals PLC is a fast growing multinational group
focused on developing, manufacturing and marketing a broad range of
both branded and non-branded generic and in-licensed pharmaceutical
products. Hikma's operations are conducted through three
businesses: "Branded", "Injectables" and "Generics". Hikma's
operations are based principally in the Middle East and North
Africa ("MENA") region, where it is a market leader and sells
across 17 countries, the United States and Europe. In 2010, the
Group achieved revenues of $731 million (2009 $637 million) and
profit attributable to shareholders was $99 million (2009 $78
million).
This information is provided by RNS
The company news service from the London Stock Exchange
END
RDNTBMJTMBTMBAT
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jun 2024 to Jul 2024
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jul 2023 to Jul 2024